구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAFFR CAR-T (BAFFR CAR-T) Guangzhou Bio-gene Technology Co.,…·B Acute Lymphoblastic Leukemia/Lym… 1 trials |
|---|---|
Overview Program | BAFFR CAR-T |
Overview Company | Guangzhou Bio-gene Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | B Acute Lymphoblastic Leukemia/Lymphoma |
Overview Indication | B Acute Lymphoblastic Leukemia/Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to s… |
Toxicology CRS | Reported |
Clinical Safety signal | Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to s… |
Clinical Program phase | PHASE_1 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BAFFR CAR-T (BAFFR CAR-T) Guangzhou Bio-gene Technology Co.,…·B Acute Lymphoblastic Leukemia/Lym… 1 trials |
|---|---|
Overview Program | BAFFR CAR-T |
Overview Company | Guangzhou Bio-gene Technology Co., Ltd |
Overview Modality | CGT |
Overview Target | B Acute Lymphoblastic Leukemia/Lymphoma |
Overview Indication | B Acute Lymphoblastic Leukemia/Lymphoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Toxicology Major finding | Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to s… |
Toxicology CRS | Reported |
Clinical Safety signal | Analysis of polyfunctionality for enhanced BAFF-R CAR T-cell therapy for hematologic malignancies.. Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising immunotherapeutic strategy for eradicating human cancers. Their therapeutic success and durability of clinical responses hinges, in large part, on their functional capacity, including the ability of these engineered cells to s… |
Clinical Program phase | PHASE_1 |
추천 비교
추천 비교